Skip to main content

Table 9 Laboratory adverse experience summary

From: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

  Sitagliptin 100 mg
n (%)
(N = 3375)
Non-Exposed
n (%)
(N = 2680)
Difference in Sitagliptin
and Non-Exposed
% (95% CI)*
With one or more adverse experiences 378 (11.2) 293 (10.9) 0.3 (-1.3, 1.8)
With drug-related adverse experiences 102 (3.0) 78 (2.9) 0.1 (-0.8, 1.0)
With serious adverse experiences 3 (0.1) 0 (0) 0.1 (-0.1, 0.3)
With serious drug-related adverse experiences 0 (0) 0 (0) 0.0 (-0.1, 0.1)
Who died 0 (0) 0 (0) 0.0 (-0.1, 0.1)
Discontinued due to adverse experiences 36 (1.1) 18 (0.7) 0.4 (-0.1, 0.9)
Discontinued due to drug-related adverse experiences 16 (0.5) 9 (0.3) 0.1 (-0.2, 0.5)
Discontinued due to serious adverse experiences 0 (0) 0 (0) 0.0 (-0.1, 0.1)
Discontinued due to serious drug-related adverse experiences 0 (0) 0 (0) 0.0 (-0.1, 0.1)
  1. CI = confidence interval
  2. *Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.
  3. Determined by the investigator to be possibly, probably, or definitely drug-related.